VERU Projected Dividend Yield
Veru Inc ( NASDAQ : VERU )Veru is a biopharmaceutical company. Co.'s infectious disease clinical development program includes: COVID-19 patients at risk for acute respiratory distress syndrome; and Sabizabulin, a microtubule disruptor. Co.'s oncology clinical development program includes: breast cancer, which consist of Enobosarm, a selective androgen receptor and Sabizabulin, a microtubule disruptor; and prostate cancer, which include Sabizabulin, a microtubule disruptor, VERU-100, a GnRH antagonist depot and Zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist. Co.'s sexual health program include ENTADFI™, for the treatment of benign prostatic hyperplasia. 24 YEAR PERFORMANCE RESULTS |
VERU Dividend History Detail VERU Dividend News VERU Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |